Current Infectious Disease Reports

, Volume 12, Issue 4, pp 299–305 | Cite as

Cryptococcal Meningitis: Current Approaches to Management in Patients With and Without AIDS

  • Kyle D. Brizendine
  • Peter G. Pappas


Cryptococcal meningitis is a life-threatening fungal infection of the central nervous system (CNS). Its management is characterized by the administration of initial combination antifungal therapy by following the principles of induction, consolidation, and maintenance therapy with aggressive management of elevated intracranial pressure (ICP). These tenets apply to patients with and without AIDS. Recent prospective trials on combination antifungal therapy, and the timing of the initiation of highly active antiretroviral therapy (HAART), suggest amphotericin B plus flucytosine and initiation of HAART are optimal therapy for management of patients with AIDS and cryptococcal meningitis. The paucity of prospective data on the management of cryptococcal meningitis in patients without AIDS is the most challenging aspect of formulating treatment guidelines, but the principles of induction, consolidation, and maintenance still apply. Combination antifungal therapy with a lipid formulation of amphotericin B plus flucytosine is generally indicated for this group, especially for those with a predisposition to renal dysfunction. Future research targeting this population may further inform recommendations.


Cryptococcal meningitis Cryptococcal meningoencephalitis Cryptococcus neoformans Cryptococcus gattii Cryptococcus Cryptococcosis Cryptococcemia Cryptococcoma Immune reconstitution inflammatory syndrome HIV AIDS Opportunistic infection Intracranial pressure 



No potential conflict of interest relevant to this article was reported.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Lortholary O, Poizat G, Zeller V, et al.: Long term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 2006, 20:2183–2191.CrossRefPubMedGoogle Scholar
  2. 2.
    •• Park BJ, Wannemuehler KA, Marston BJ, et al.: Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525–530, This article provides an excellent recent characterization of the true global impact of cryptococcosis.CrossRefPubMedGoogle Scholar
  3. 3.
    •• Perfect JR, Dismukes WE, Dromer F, et al.: Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:291–322, This article is an outstanding review of the management of cryptococcosis including both cryptococcal meningitis and non-CNS cryptococcal disease.CrossRefPubMedGoogle Scholar
  4. 4.
    Van der Horst CM, Saag MS, Cloud GA, et al.: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997, 337:15–21.CrossRefPubMedGoogle Scholar
  5. 5.
    Saag MS, Powderly WG, Cloud GA, et al.: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992, 326:83–89.PubMedCrossRefGoogle Scholar
  6. 6.
    •• Brouwer AE, Rajanuwong A, Chierakul W, et al.: Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomized trial. Lancet 2004, 363:1764–1767, This article is the first paper to define EFA and its use as well as test and compare combination antifungal therapy based on clearance of cryptococcal CFU from CSF.CrossRefPubMedGoogle Scholar
  7. 7.
    Robinson PA, Bauer M, Leal MA, et al.: Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999, 28:82–92.CrossRefPubMedGoogle Scholar
  8. 8.
    •• Bicanic T, Wood R, Meintjes G, et al.: High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008, 47:123–130, This article describes a prospective trial evaluating two separate amphotericin B doses using the cryptococcal CFU clearance rate from the CSF (EFA) as an endpoint.CrossRefPubMedGoogle Scholar
  9. 9.
    • Bicanic T, Muzoora C, Brouwer AE, et al.: Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009, 49:702–709, This article reports a combined cohort of patients for whom cryptococcal CFU clearance rate from the CSF (EFA) was known and shown to be associated with 2-week and 10-week mortality.CrossRefPubMedGoogle Scholar
  10. 10.
    • Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O: Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS ONE 2008, 3:1–9, This article reports a prospective observational trial evaluating outcomes of patients who did or did not receive flucytosine as part of combination antifungal therapy for cryptococcosis.CrossRefGoogle Scholar
  11. 11.
    Saag MS, Graybill RJ, Larsen RA, et al.: Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000, 30:710–718.CrossRefPubMedGoogle Scholar
  12. 12.
    Milefchik E, Leal MA, Haubrich R, et al.: Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 2008, 46:393–395.CrossRefPubMedGoogle Scholar
  13. 13.
    • Nussbaum JC, Jackson A, Namarika D, et al.: Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 2010, 50:338–344, This article describes a prospective trial evaluating the optimal oral regimen for cryptococcal meningitis.CrossRefPubMedGoogle Scholar
  14. 14.
    Pappas PG: Fluconazole plus amphotericin B vs amphotericin B alone for primary treatment of AIDS-associated cryptococcal meningitis: results of a phase II trial [abstract M626]. In Program and abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 2007.Google Scholar
  15. 15.
    Baddour LM, Perfect JR, Ostrosky-Zeichner L: Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis 2005, 40(Suppl 6):S409–S413.CrossRefPubMedGoogle Scholar
  16. 16.
    Coker RJ, Viviani M, Gazzard BG, et al.: Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993, 7:829–835.CrossRefPubMedGoogle Scholar
  17. 17.
    Bicanic T, Meintjes G, Rebe K, et al.: Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009, 51:130–134.CrossRefPubMedGoogle Scholar
  18. 18.
    Zolopa AR, Andersen J, Komarow L, et al.: Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE 2009, 4:1–10.CrossRefGoogle Scholar
  19. 19.
    •• Sungkanuparph S, Filler SG, Chetchotisakd P, et al.: Cryptococcal immune reconstitution syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis 2009, 49:931–934, This article describes a prospective study evaluating the timing and outcomes of IRIS associated with cryptococcal meningitis in HIV-positive patients who begin HAART.CrossRefPubMedGoogle Scholar
  20. 20.
    Graybill JR, Sobel J, Saag MS, et al.: Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000, 30:47–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Sun HY, Hung CC, Chang SC: Management of cryptococcal meningitis with extremely high intracranial pressure in HIV-infected patients. Clin Infect Dis 2004, 38:1790–1792.CrossRefPubMedGoogle Scholar
  22. 22.
    Husain S, Wagener MM, Singh N: Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001, 7:375–381.CrossRefPubMedGoogle Scholar
  23. 23.
    Vilchez RA, Fung J, Kusne S: Cryptococcosis in organ transplant recipients: an overview. Am J Transplant 2002, 2:575–580.CrossRefPubMedGoogle Scholar
  24. 24.
    Singh N, Lortholary O, Alexander BD, et al.: Antifungal management practices and evolution of infection in organ transplant recipients with Cryptococcus neoformans infection. Transplantation 2005, 80:1033–1039.CrossRefPubMedGoogle Scholar
  25. 25.
    Ecevit IZ, Clancy CJ, Schmalfuss IM, Nguyen MH: The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy. Clin Infect Dis 2006, 42:1443–1447.CrossRefPubMedGoogle Scholar
  26. 26.
    MacDougall L, Kidd SE, Galanis E, et al.: Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis 2007, 13:42–50.CrossRefPubMedGoogle Scholar
  27. 27.
    Chen S, Sorrell T, Nimmo G, et al.: Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 2000, 31:499–508.Google Scholar
  28. 28.
    Speed B, Dunt D: Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995, 21:28–34.PubMedGoogle Scholar
  29. 29.
    Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525–530.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Medicine, Division of Infectious DiseasesUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations